- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07683793
A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants
An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Chiesi Clinical trial Info
- Telefonnummer: +390521279715
- E-post: clinicaltrials_info@chiesi.com
Studieorter
-
-
-
Leeds, Storbritannien
- Fortrea Clinical Research Unit (CRU) Limited
-
Kontakt:
- Firas Almezedi
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Beskrivning
Key Inclusion Criteria:
- BMI (body mass index) between 18.0 and 30.0 kg/m²
- Weight between 45 and 100 kg
- Non-smokers or ex-smokers (<5 pack-years)
- Clinically healthy based on medical history and examination
- Normal vital signs
- Normal ECG
- Willingness to comply with contraception requirements
Key Exclusion Criteria:
- Recent participation in another clinical study
- Significant medical conditions
- Abnormal laboratory values
- Positive HIV or hepatitis tests
- Recent infection or COVID-19
- Drug or alcohol abuse
- Use of prohibited medications
- Gastrointestinal surgery affecting absorption
- Hypersensitivity to study drugs
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Fixed Sequence Treatment
CHF10196 - Pantoprazole - Pantoprazole with CHF10196
|
Treatment Period 1: CHF10196 single dose administration on Day1; Treatment Period 2: CHF10196 single dose administration after pantoprazole single dose administration on Day13 Treatment Period 2: Pantoprazole single dose administration from Day8 to Day13 |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PK parameter: AUC0-∞
Tidsram: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: AUC0-t
Tidsram: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the plasma concentration time curve from time 0 to last quantifiable concentration (AUC0-t) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: Cmax
Tidsram: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for maximum observed concentration when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Safety and tolerability: Incidence of adverse events (AE)
Tidsram: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number and percentage of adverse events (AE) when CHF10196 administered alone and when administered with pantoprazole
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs: PR
Tidsram: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in PR (pulse rate), by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - RR
Tidsram: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs: RR (respiratory rate) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - blood pressure
Tidsram: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for ECG
Tidsram: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baselines in milliseconds (ms). Intervals recorded: PR , RR, QT, QTc, QRS duration, QTcF (Fridericia-corrected QT interval Baselines (the last value before the first administration of any CHF10196 of each treatment period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196 |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for ECG (HR)
Tidsram: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baseline for ECG recording of heart rate (HR) Baselines (the last value before the first administration of any CHF10196 of each Treatment Period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196). |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for laboratory abnormalities
Tidsram: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number of participants with abnormal blood laboratory test results.
Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: AUC0-24h
Tidsram: From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
comparing the ratio of adjusted geometric means for the area under the plasma concentration time curve from time 0 to 24 h post-dose when CHF10196 administered alone and when administered with pantoprazole (with their 90% two-sided Confidence Intervals)
|
From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
|
Additional pharmacokinetic parameters: CL/F
Tidsram: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the total body clearance (CL/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: t1/2
Tidsram: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the terminal half-life (t1/2) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: Vd/F
Tidsram: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the apparent volume of distribution (Vd/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: tmax
Tidsram: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Evaluating the Hodges-Lehmann non-parametric estimate of location shift between CHF10196 with pantoprazole (test) and CHF10196 alone (reference) in median time corresponding to maximum plasma when CHF10196 administered alone and when administered with pantoprazole concentration (tmax)
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Benjamen Monaghan, Fortrea Clinical Research Unit (CRU)
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CLI-10196AA1-05
- 1014440 (Annan identifierare: IRAS)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .